Ghoshal UC, Singh R, Rai S. Prevalence and risk factors of gastroesophageal reflux disease in a rural Indian population. Indian J Gastroenterol. 2021;40:56–64.
Rai S, Kulkarni A, Ghoshal UC. Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: A meta-analysis and meta-regression study. Indian J Gastroenterol. 2021;40:209–19.
Karyampudi A, Ghoshal UC, Singh R, Verma A, Misra A, Saraswat VA. Esophageal acidification during nocturnal acid-breakthrough with Ilaprazole versus Omeprazole in gastroesophageal reflux disease. J Neurogastroenterol Motil. 2017;23:208–17.
Ghoshal UC, Chourasia D, Tripathi S, Misra A, Singh K. Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: a study using 24-h dual-channel pH-metry. Scand J Gastroenterol. 2008;43:654–61.
Naik RD, Evers L, Vaezi MF. Advances in the diagnosis and treatment of GERD: New tricks for an old disease. Curr Treat Options Gastroenterol. 2019;17:1–17.
Scarpignato C, Hongo M, Wu JCY, et al. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci. 2020;1482:193–212.
Bhatia SJ, Reddy DN, Ghoshal UC, et al. Epidemiology and symptom profile of gastroesophageal reflux in the Indian population: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2011;30:118–27.
Ghoshal UC, Chourasia D. Genetic factors in the pathogenesis of gastroesophageal reflux disease. Indian J Gastroenterol. 2011;30:55–62.
Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179.
Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001;15:1351–6.
Peura DA, Pilmer B, Hunt B, Mody R, Perez MC. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;38:1303–11.
Goh KL, Choi MG, Hsu PI, et al. Pharmacological and safety profile of Dexlansoprazole: A new proton pump inhibitor - Implications for treatment of gastroesophageal reflux disease in the Asia Pacific Region. J Neurogastroenterol Motil. 2016;22:355–66.
Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011;106:421–31.
Mermelstein J, Mermelstein AC, Chait MM. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole. Clin Exp Gastroenterol. 2016;9:163–72.
Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003;98:545–50.
Bhatia SJ, Makharia GK, Abraham P, et al. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol. 2019;38:411–40.
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20; quiz 43.
Ghoshal UC, Singh R. Catheter-based 24-h pH-metry and impedance: Technique, interpretation, and clinical application. In: Evaluation of Gastrointestinal Motility and its Disorders: (Ed. Ghoshal UC) Springer, India. 2016:95-106..
Hill HF, Chapman CR, Jackson TL, Sullivan KM. Assessment and management of donor pain following marrow harvest for allogeneic bone marrow transplantation. Bone Marrow Transplant. 1989;4:157–61.
Weigt J, Kandulski A, Busch F, Malfertheiner P. Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients. Dig Dis. 2009;27:68–73.
Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion. 1992;51 Suppl 1:59-67.
Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998;12:1235–40.
Matveev VI. Method of measured administration of radioactive aerosols to dogs. Gig Sanit. 1971;36:69-72.
Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42:676–9.
Hoshino E, Ishiyama A, Tsuchida T. PPI: new strategies for GERD. Nihon rinsho Jpn J Clin Med. 2004;62:1570–6.
Ghoshal UC, Chourasia D. Gastroesophageal reflux disease and Helicobacter pylori: What may be the relationship? J Neurogastroenterol Motil. 2010;16:243–50.
Chourasia D, Misra A, Tripathi S, Krishnani N, Ghoshal UC. Patients with Helicobacter pylori infection have less severe gastroesophageal reflux disease: a study using endoscopy, 24-hour gastric and esophageal pH metry. Indian J Gastroenterol. 2011;30:12–21.
Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90: 1401–6.
Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut. 2000;46:615–21.
Armstrong D, Marshall JK, Chiba N, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol. 2005;19:15–35.
Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16:800–8 e7.
Shetkar SS, Ramakrishnan S, Seth S, et al. CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease. Indian Heart J. 2014;66:16–24.